FierceBiotech Jun 8, 2026 How Unlearn is building a scientific intelligence layer for clinical development
Roche Media Jun 8, 2026 Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology
Brady Corporation Jun 8, 2026 Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 - The Manila Times
Endpoints News Jun 8, 2026 Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
Endpoints News Jun 8, 2026 Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal
FierceBiotech Jun 8, 2026 ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
FierceBiotech Jun 8, 2026 Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
BioPharma Dive Jun 8, 2026 Precision under pressure: Logistic solutions for nuclear medicine scalability
Lonza News Jun 8, 2026 Lonza and Stipple Bio strike licensing deal for precision oncology ADCs - BioXconomy
Roche Media Jun 8, 2026 Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown - Fierce Biotech
Roche Media Jun 8, 2026 Roche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.com